| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $60,043,476 ) (Continued on the next page) |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | P50CA136393 | Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancer | 002 | 14 | NIH | 1/7/2025 | $210,627 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01NS076491 | Computational and Biological Approach to Flow Diversion | 000 | 14 | NIH | 11/29/2024 | $398,331 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG083832 | Automated speech assessment for diagnosis of FTD spectrum disorders | 000 | 2 | NIH | 1/15/2025 | $723,711 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA273027 | Role of MALT1 in regulating the breast cancer immune microenvironment | 002 | 3 | NIH | 11/29/2024 | $485,171 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK131685 | Noninvasive assessment of detrusor pressure and dysfunction | 000 | 4 | NIH | 12/23/2024 | $566,479 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA256927 | Targeting dual functions of PD-L1 for cancer therapy | 000 | 5 | NIH | 11/29/2024 | $327,341 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL160570 | Hydrogen Sulfide in Neonatal Airway Disease | 000 | 3 | NIH | 12/6/2024 | $536,787 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA275870 | Investigating the role of MAP2 in chemotherapy-induced peripheral neurotoxicity | 000 | 3 | NIH | 1/7/2025 | $559,858 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL171056 | INTEGRATION OF MECHANICAL AND MOLECULAR CUES DURING DISTAL LUNG DEVELOPMENT | 000 | 2 | NIH | 12/23/2024 | $532,264 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R37EB001981 | Magnetic Resonance Elastography | 000 | 24 | NIH | 11/26/2024 | $357,750 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01NS129549 | Development of an innovative in vivo voltammetric technique for measurements of tonic serotonin concentrations in the mammalian brain. | 000 | 3 | NIH | 12/26/2024 | $521,739 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA132878 | Post-translational Modifications in DNA Damage Response: a Structural Perspective | 000 | 12 | NIH | 1/13/2025 | $363,150 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AI089714 | Inflammatory cascades disrupt Treg function through epigenetic mechanisms | 000 | 15 | NIH | 12/20/2024 | $464,261 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R03AG091264 | Blood plasma metrics as disease biomarkers in atypical Alzheimer's disease | 000 | 1 | NIH | 12/20/2024 | $320,143 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG090601 | Prescription opioids, brain structure, and cognition in older adults with chronic pain | 000 | 1 | NIH | 12/20/2024 | $636,957 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F32DK135200 | Factors influencing positive change in glycemic control and Type 2 diabetes self-management behavior among Latinx individuals in a digital storytelling intervention: A mixed-methods study | 000 | 2 | NIH | 11/25/2024 | $77,284 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01GM144351 | Methods for microbiome compositional data | 000 | 4 | NIH | 12/20/2024 | $295,083 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA269384 | Re-purposing Oncolytic Virotherapy to Re-invigorate CAR T Cell Therapy for Solid Tumors. | 000 | 3 | NIH | 11/25/2024 | $327,341 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA249116 | ERβ repurposes EZH2 to suppress oncogenic NFκB signaling in TNBC | 000 | 5 | NIH | 1/1/2025 | $440,011 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA282702 | Clonal growth and prediction of monoclonal B-cell lymphocytosis | 000 | 2 | NIH | 3/3/2025 | $173,737 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K23MD016230 | Rural Patient Risks and Exposures for Diabetes ConTrol (Rural PREDICT) | 000 | 5 | NIH | 2/18/2025 | $146,896 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL172948 | Understanding and addressing the lack of and delayed screening for primary Aldosteronism | 000 | 1 | NIH | 2/24/2025 | $726,611 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG087140 | Neuroinflammation, white matter integrity, AD biomarkers and pathology in corticobasal syndrome | 000 | 1 | NIH | 3/27/2025 | $798,032 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL167796 | Targeting Senescence Specific Mechanisms of NF-κB Activation to Reverse Chronic Pulmonary Fibrosis | 000 | 2 | NIH | 3/5/2025 | $530,118 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG076469 | A novel cilium-to-nucleus axis promotes cellular senescence | 000 | 4 | NIH | 3/6/2025 | $293,355 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK126206 | The effect of endogenous GLP-1 secretion on islet function in vivo | 000 | 6 | NIH | 3/5/2025 | $648,316 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL166238 | Electrochemical Catheter for Prevention of Central Line-Associated Bloodstream Infection | 000 | 3 | NIH | 2/19/2025 | $382,186 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL145268 | Measuring arterial material properties using wave-based approaches with ultrasound and computational models | 000 | 7 | NIH | 2/26/2025 | $616,578 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK137231 | Engineering microcapsules for scalable differentiation of human pluripotent stem cells into hepatocytes | 000 | 2 | NIH | 2/20/2025 | $500,141 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U10CA180882 | Alliance Statistics and Data Management Center | 000 | 11 | NIH | 3/14/2025 | $4,779,823 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK132718 | Noninvasive assessment of portal hypertension and hepatic interstitial pressure with advanced magnetic resonance elastography | 000 | 3 | NIH | 2/27/2025 | $310,878 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA272496 | Targeting PLK1 in RAS mutant chronic myelomonocytic leukemia | 000 | 3 | NIH | 3/14/2025 | $384,419 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | UG1CA232760 | NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1 (funded extension) | 001 | 6 | NIH | 3/18/2025 | $590,417 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG050603 | Molecular and structural imaging in atypical Alzheimer's disease: a longitudinal study | 000 | 10 | NIH | 3/18/2025 | $714,049 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG069052 | "What is N?" Towards operationalizing neurodegeneration in Alzheimer's and related dementias | 000 | 3 | NIH | 3/18/2025 | $668,066 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | P01AG062413 | Targeting Cellular Senescence to Extend Healthspan | 000 | 7 | NIH | 3/12/2025 | $3,168,053 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA285345 | Mechanism and therapeutic targeting of castration resistance in SPOP-mutated prostate cancer | 000 | 2 | NIH | 3/18/2025 | $442,842 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R37CA261854 | NAD+ metabolism in PARP inhibitor resistance of ovarian cancer | 000 | 5 | NIH | 3/25/2025 | $382,174 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB031790 | Super Resolution for Improved Multislice Prostate MRI | 000 | 4 | NIH | 3/17/2025 | $560,204 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB036987 | AI-assisted quantitative photon-counting-detector CT imaging for cytogenetic risk prediction and treatment response in multiple myeloma | 000 | 1 | NIH | 3/19/2025 | $546,874 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA283539 | RNA methylation as a novel effector of SETD2 in kidney cancer | 000 | 2 | NIH | 3/20/2025 | $169,773 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL084155 | Human Cardiorenal Syndrome | 000 | 13 | NIH | 3/28/2025 | $397,102 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U01CA246568 | Utility of memantine in preventing cognitive dysfunction in children receiving cranial radiotherapy | 000 | 6 | NIH | 3/28/2025 | $287,216 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA275074 | Evaluation of novel tomosynthesis density measures in breast cancer risk prediction | 000 | 3 | NIH | 3/19/2025 | $604,359 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DC014942 | The neurobiology of two distinct subtypes of neurodegenerative apraxia of speech: phenotypes of Alzheimer disease related 4-repeat tauopathies | 000 | 8 | NIH | 3/19/2025 | $579,047 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG081584 | Biophysically inspired mechanical biomarkers of normal pressure hydrocephalus | 000 | 2 | NIH | 3/20/2025 | $363,150 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R37CA266344 | Towards Safer and More Effective CART Cell Therapy Through the Modulation of Myeloid Cytokines | 001 | 4 | NIH | 2/12/2025 | $0 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA248147 | Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancer | 001 | 5 | NIH | 2/14/2025 | $0 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK122948 | Lipotoxicity and Liver Inflammation | 001 | 6 | NIH | 2/28/2025 | $525,565 |
|
